Skip to content

A clinical study to evaluate the safety and effectiveness of Amrutveni DandroQit shampoo in reducing dandruff and improving scalp condition in adults with mild to moderate dandruff

A Single-Arm, Open-Label, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Amrutveni DandroQit shampoo in the Management of Mild to Moderate Dandruff - nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/097275
Enrollment
36
Registered
2025-11-12
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L20-L30- Dermatitis and eczema

Interventions

Intervention1: Amrutveni DandroQit Shampoo: Type: Topical herbal shampoo formulation Dosage Form: shampoo (for external application on scalp) Route of Administration: Topical application on scalp Mode

Sponsors

Sahyadri Bio Labs Pvt.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Male and female participants aged 10 to 55 years. 2. Clinical diagnosis of mild to moderate dandruff, defined by a Flake Severity Score (FSS) of 1–3. 3. Willingness to abstain from using any other hair care or anti-dandruff products throughout the study duration. 4. Voluntary participation with written informed consent.

Exclusion criteria

Exclusion criteria: 1. Participants with other known scalp disorders (e.g., psoriasis, seborrheic dermatitis, tinea capitis). 2. Individuals with known hypersensitivity or allergy to any of the shampoo components. 3. Use of systemic corticosteroids, antifungals, or antibiotics in the past 4 weeks. 4. Participation in another clinical study in the last 30 days. 5. Pregnant or lactating women.

Design outcomes

Primary

MeasureTime frame
Change in Dandruff Severity Index (DSI; 0–9, clinician-rated) from baseline (Day 0) to end of treatment (Day 21).Timepoint: Day 0 (Baseline), Days 1–7 (daily symptom/safety tracking), Day 7, Day 14, and Day 21 (end of treatment).

Secondary

MeasureTime frame
1. Pruritus Assessment (VAS) 2. Subjective Hair Manageability Questionnaire 3. Wet Combability Test 4. Ocular Irritation Scale 5. Investigator Global Assessment (IGA) 6. Subject Self-Assessment Questionnaire 7. Hair Strand Health Assessment 8. Cosmetic Outcome Evaluation Timepoint: Day 0 (Baseline), Days 1–7 (daily symptom/safety tracking), Day 7, Day 14, and Day 21 (end of treatment).

Countries

India

Contacts

Public ContactDr Kasthuri Nair A

Pankajakasthuri Ayurveda Medical college and PG centre

dr.kasthurinair@pkhil.com8113851665

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026